证券日报网讯 12月16日，新天药业在互动平台回答投资者提问时表示，公司目前正按计划推进创新药 研发进度。其中用于治疗癌因性疲乏的欣力康胶囊已于2025年10月获得药监部门下发的药物临床试验批 准通知书，获准开展临床实验研究工作。 （编辑 王雪儿） ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司的创新药研发进展情况怎么样？ 新天药业（002873.SZ）12月16日在投资者互动平台表示，公司目前正按计划推进创新药研发进度。其 中用于治疗癌因性疲乏的欣力康胶囊已于2025年10月获得药监部门下发的药物临床试验批准通知书，获 准开展临床实验研究工作。 ...

Core Viewpoint - New Tian Pharmaceutical has received approval for clinical trials of its Xinlikang capsules, which are aimed at treating cancer-related fatigue in colorectal cancer patients, potentially accelerating the development of its innovative drug pipeline and creating new growth opportunities for the company [2][4]. Group 1: Clinical Trial Approval - The Xinlikang capsules (CXZL2500054) have been approved for clinical trials to treat cancer-related fatigue, enhancing their therapeutic indications for colorectal cancer patients [2][4]. - The approval is expected to expedite the research and development process for the company's innovative drug pipeline, which may lead to new revenue streams [2][5]. Group 2: Market Demand and Potential - Cancer-related fatigue (CRF) is a significant clinical symptom affecting cancer patients, with incidence rates reaching 40% during diagnosis, 62%-85% during treatment, and 30% during follow-up [3]. - The market for CRF treatment in China is projected to reach 18 billion yuan by 2025, indicating a substantial unmet clinical need [5]. - If Xinlikang successfully gains approval for treating CRF in colorectal cancer patients, it has the potential to become a billion-yuan product due to the high prevalence of colorectal cancer [6]. Group 3: R&D Investment and Pipeline - New Tian Pharmaceutical has significantly increased its R&D investment over the past five years, positioning itself as a leader in traditional Chinese medicine innovation [6]. - The company currently has over 10 proprietary products in its pipeline, including several innovative traditional Chinese medicines in various stages of clinical trials [6][7]. - In 2024, New Tian Pharmaceutical's R&D expenses are projected to be 40 million yuan, with a research expense ratio of 4.7%, ranking it among the top in its category [6].

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of Xinlikang capsules aimed at treating cancer-related fatigue [2] Company Summary - Xinlikang capsules have been granted a clinical trial approval notification, indicating progress in the company's research and development efforts [2] - The focus of the clinical trial is on treating cancer-related fatigue, which highlights the company's commitment to addressing significant health issues [2] Industry Summary - The approval for clinical trials reflects ongoing advancements in the pharmaceutical industry, particularly in the development of treatments for cancer-related symptoms [2] - This development may indicate a growing market for therapies targeting cancer-related fatigue, potentially leading to increased investment and interest in this area of healthcare [2]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its proprietary drug, Xinkang Capsules, aimed at treating cancer-related fatigue [1] Company Summary - Xinkang Capsules are an exclusive proprietary medicine developed by the company, presented in a capsule form with a specification of 0.45g per capsule [1] - The drug is a result of the company's independent research and development efforts in traditional Chinese medicine [1] Industry Summary - The approval for clinical trials indicates a potential advancement in the treatment options available for cancer-related fatigue, which may enhance the company's position in the pharmaceutical market [1]

Core Viewpoint - Xintian Pharmaceutical (002873.SZ) has received approval from the National Medical Products Administration for clinical trials of Xinkang Capsules, aimed at treating cancer-related fatigue in colon cancer patients [1] Group 1: Company Developments - The approval allows Xintian Pharmaceutical to conduct clinical trials to validate the efficacy of Xinkang Capsules for treating cancer-related fatigue (CRF) [1] - Cancer-related fatigue is defined as a painful, persistent sense of exhaustion that cannot be alleviated by rest, often accompanied by cognitive impairment and emotional distress [1] Group 2: Industry Context - The clinical practice guidelines for cancer-related fatigue in China (2021 edition) outline the characteristics and impact of CRF on patients' daily lives [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of Xinlikang capsules, aimed at treating cancer-related fatigue [1] Group 1 - The approval allows the company to conduct clinical trials for Xinlikang capsules [1] - The indication for the clinical trial is specifically for the treatment of cancer-related fatigue [1]

Group 1 - The core point of the article is that Xintian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its Xinlikang capsules, aimed at treating cancer-related fatigue [1] - As of October 14, Xintian Pharmaceutical's market capitalization is 2.6 billion yuan [2] - For the first half of 2025, Xintian Pharmaceutical's revenue composition shows that main business revenue accounts for 99.9%, while other business revenue accounts for 0.1% [1]

Core Viewpoint - The company Xin Tian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its Xin Likang capsules, aimed at treating cancer-related fatigue [1] Group 1 - The company has announced the receipt of a clinical trial approval notice for Xin Likang capsules [1] - The clinical trial is specifically for the treatment of cancer-related fatigue [1]

Core Viewpoint - The company Xin Tian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its Xin Likang capsules, aimed at treating cancer-related fatigue [1] Group 1 - The approval allows the company to conduct clinical trials for Xin Likang capsules [1] - The indication for the clinical trial is specifically for the treatment of cancer-related fatigue [1]